Synthesis and toxicopharmacological evaluation of m-Hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1418-1422

  Catalano, Alessia ^a   Desaphy, Jean François ^a   Lentini, Giovanni ^a   Carocci, Alessia ^a   Di Mola, Antonia ^a   Bruno, Claudio ^a   Carbonara, Roberta ^a   De Palma, Annalisa ^a   Budriesi, Roberta ^b   Ghelardini, Carla ^c   Perrone, Maria Grazia ^a   Colabufo, Nicola Antonio ^a   Conte Camerino, Diana ^a   Franchini, Carlo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYMEXILETINE; DRUG METABOLITE; MEXILETINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; AORTA; ATAXIA; BLOOD-BRAIN BARRIER; CACO-2 CELLS; GUINEA PIGS; HEART; HEART RATE; HEK293 CELLS; HUMANS; ION CHANNEL GATING; MEXILETINE; MICE; P-GLYCOPROTEIN; PERMEABILITY; SODIUM CHANNELS; STEREOISOMERISM; VASODILATOR AGENTS;

EID: 84856870843     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201197z     Document Type: Article

References (37)

1. Hughes, B. 2008 FDA drug approvals Nat. Rev. Drug Discovery 2009, 8, 93-96
2. Di Masi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs J. Health. Econ. 2003, 22, 151-185 (Pubitemid 36279392)
3. Tucker, G. T. Chiral switches Lancet 2000, 355, 1085-1087 (Pubitemid 30162817)
4. Brodie, B. B.; Axelrod, J. The fate of acetophenetidin (phenacetin) in man and methods for the estimation of acetophenetidin and its metabolites in biological materials J. Pharmacol. Exp. Ther. 1949, 97, 58-67
5. Teague, S. J. Learning lessons from drugs that have recently entered the market Drug Discovery Today 2011, 16, 398-411
6. Yamauchi, M.; Watanabe, E.; Yasui, K.; Takeuchi, H.; Terasawa, T.; Sawada, K.; Hishida, H.; Kodama, I. Prevention of ventricular extrasystole by mexiletine in patients with normal QT intervals is associated with a reduction of transmural dispersion of repolarization Int. J. Cardiol. 2005, 103, 92-97 (Pubitemid 41074611)
7. Fenster, P. E.; Comess, K. A. Evaluations of new drugs Pharmacotherapy 1986, 6, 1-9
8. Sloan, P.; Basta, M.; Storey, P.; von Gunten, C. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain Anesth. Analg. 1999, 89, 760-761 (Pubitemid 29409837)
9. Jarvis, B.; Coukell, A. J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy Drugs 1998, 56, 691-707 (Pubitemid 28488270)
10. Oskarsson, P.; Ljiunggren, J.-G.; Lins, P.-E. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy Diabetes Care 1997, 20, 1594-1597 (Pubitemid 27415040)
11. Tremont-Lukats, I. W.; Challapalli, V.; McNicol, E. D.; Lau, J.; Carr, D. B. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis Anesth. Analg. 2005, 101, 1738-1749 (Pubitemid 41722151)
12. Rüdel, R.; Lehmann-Horn, F. Membrane changes in cells from myotonia patiens Physiol. Rev. 1985, 65, 310-356 (Pubitemid 15081127)
13. Lehmann-Horn, F.; Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease Physiol. Rev. 1999, 79, 1317-1372 (Pubitemid 29473318)
14. Chrestian, R.; Puymirat, J.; Bouchard, J.-P.; Dupré, N. Myotonia congenital-a cause of muscle weakness and stiffness Nat. Clin. Pract. Neurol. 2006, 2, 393-399 (Pubitemid 43983777)
15. Gay, S.; Dupuis, D.; Faivre, L.; Masurel-Paulet, A.; Labenne, M.; Colombani, M.; Soichot, P.; Huet, F.; Hainque, B.; Sternberg, D.; Fontaine, B.; Gouyon, J.-B.; Thuvin-Robinet, C. Severe neonatal non-distrophic myotonic secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene Am. J. Med. Genet., Part A 2008, 146, 380-383 (Pubitemid 351212841)
16. Akinci, E.; Yüzbaşioglu, Y.; Coşkun, F. Hemodialysis as an alternative treatment of mexiletine intoxication Am. J. Emerg. Med. 2011, 29, 1235-1236
17. Labbè, L.; Turgeon, J. Clinical pharmacokinetics of mexiletine Clin. Pharmacokinet. 1999, 37, 361-384
18. Beckett, A. H.; Chidomere, E. C. The distribution, metabolism and excretion of mexiletine in man Postgrad. Med. J. 1977, 53 (Suppl. 1) 60-66
19. Beckett, A. H.; Chidomere, E. C. The identification and analysis of mexiletine and its metabolic products in man J. Pharm. Pharmacol. 1977, 29, 281-285 (Pubitemid 8083885)
20. Campbell, N. P.; Kelly, J. G.; Adgey, A. A.; Shanks, R. G. The clinical pharmacology of mexiletine Br. J. Clin. Pharmacol. 1978, 6, 103-108 (Pubitemid 8401083)
21. Hashimoto, K. Mexiletine New Cardiovasc. Drugs 1986, 141-161
22. Kates, R. E. Metabolites of cardiac antiarrhythmic drugs: their clinical role Ann. N.Y. Acad. Sci. 1984, 432, 75-89 (Pubitemid 15157257)
23. Catalano, A.; Carocci, A.; Fracchiolla, G.; Franchini, C.; Lentini, G.; Tortorella, V.; De Luca, A.; De Bellis, M.; Desaphy, J.-F.; Conte Camerino, D. Stereospecific synthesis of para-hydroxymexiletine and sodium channel blocking activity evaluation Chirality 2004, 16, 72-78 (Pubitemid 38134069)
24. Cavalluzzi, M. M.; Catalano, A.; Bruno, C.; Lovece, A.; Carocci, A.; Corbo, F.; Franchini, C.; Lentini, G.; Tortorella, V. Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine, one of the major metabolites of mexiletine Tetrahedron: Asymmetry 2007, 18, 2409-2417 (Pubitemid 350018998)
25. De Bellis, M.; De Luca, A.; Rana, F.; Cavalluzzi, M. M.; Catalano, A.; Lentini, G.; Franchini, C.; Tortorella, V.; Conte Camerino, D. Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents Br. J. Pharmacol. 2006, 149, 300-310 (Pubitemid 44453431)
26. Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A.; Amoroso, R.; Franchini, C.; Lentini, G.; Tortorella, V. Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction Tetrahedron: Asymmetry 2000, 11, 3619-3634
27. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products Synthesis 1981, 1-28
28. Adejare, A.; Sciberras, S. S. Synthesis and β-adrenergic activities of R -fluoronaphtyloxypropanolamine Pharm. Res. 1997, 14, 533-536
29. Logan, M. E.; Oinen, M. E. Dechlorination of aryl chlorides with sodium formate using a homogeneous palladium catalyst Organometallics 2006, 25, 1052-1054
30. 2O) modification: synthesis and biological activity J. Med. Chem. 1991, 34, 2430-2438
31. Grech-Bélanger, O.; Turgeon, J.; Lalande, M.; Bélanger, P. M. Meta-hydroxymexiletine, a new metabolite of mexiletine Drug. Metab. Dispos. 1991, 19, 458-461
32. Desaphy, J.-F.; Dipalma, A.; Costanza, T.; Bruno, C.; Lentini, G.; Franchini, C.; George, A. L., Jr.; Conte Camerino, D. Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide Br. J. Pharmacol. 2010, 160, 1521-1533
33. Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic Calculations with Computer Programs, 2 nd ed.; Springer-Verlag: New York, 1987.
34. Colabufo, N. A.; Berardi, F.; Cantore, M.; Perrone, M. G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G. M.; Porcelli, L.; Paradiso, A. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives Bioorg. Med. Chem. 2008, 16, 362-373
35. Franklin, R.; Golding, B. T.; Tyson, R. G. Mexiletine Amino Acid and Peptide Prodrugs and Uses Thereof. Patent WO 2010/149760, 2010.
36. Carocci, A.; Franchini, C.; Lentini, G.; Loiodice, F.; Tortorella, V. Facile entry to (-)-(R)- and (+)-(S)-mexiletine Chirality 2000, 12, 103-106 (Pubitemid 30140802)
37. Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution J. Org. Chem. 1978, 43, 2923-2925